ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0568

Coexistence of Raynaud’s Phenomenon, Morphea or Scleroderma in Spondyloarthritis Patients: Insights from a Retrospective Cohort Study Highlighting a Unique Phenotype

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0624

Coexisting Tubulointerstitial Inflammation and Damage Is a Risk Factor for Chronic Kidney Disease in Patients with Lupus Nephritis

SLE – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0180

Collaborative Solutions to Lupus Trial Challenges for Underrepresented Participant Recruitment & Engagement: Perspectives from the Lupus Clinical Investigators Network (LuCIN)

Healthcare Disparities in Rheumatology Poster I

10:30AM-12:30PM: Abstract Number: 0575

Combined Testing of anti-CD74 IgA and Anti-UH-axSpA Antibodies Increases the Diagnostic Potential for axSpA

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0145

Community Mobility in a Diverse Cohort of Individuals with Systemic Lupus Erythematosus

Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0519

Comparable Malignancy Risk of Janus Kinase Inhibitors with Conventional Synthetic and Biologic DMARDs in Asian Patients with Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0155

Comparative Analysis and Outcomes of COVID 19: Unveiling Trends in Rheumatological vs. Non-Rheumatological Disease Patients

Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0382

Comparative Analysis of Tear-based S100 Proteins, Cytokines, and Chemokines Levels in Juvenile Idiopathic Arthritis Associated-uveitis: Insights into Eye Laterality and Severity of Ocular Inflammation

Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0082

Comparative Immunology of Entheseal Anchorage Sites Between Spine, Hip and Knee Demonstrates up to 70-fold Greater IL-23 Induction from Axial Enthesis Bone: A New Angle on the Failure of IL-23 Blockade in Ankylosing Spondylitis

SpA Including PsA – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 0111

Comparative Performance of ELISA and CLIA Against the 2023 ACR/EULAR APS Classification Criteria

Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0363

Comparative Risk of Demyelinating Diseases Among Patients on TNF-Alpha Inhibitors: A Cohort Study Using the TriNetX Database

Patient Outcomes, Preferences, & Attitudes Poster I

10:30AM-12:30PM: Abstract Number: 0061

Comparative Transcriptional Profiling of IPF and RA-ILD Lung Tissue Demonstrates Both Overlapping and Distinct Cell-specific Signaling Pathways

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0320

Comparative Transcriptional Profiling Reveals Shared Pathway Activation Between Human Jo-1+ Anti-Synthetase Syndrome and Murine Histidyl-tRNA Synthetase-Induced Myositis

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0403

Comparing Domains Reported by Patients and Other Collaborators in CNO and SAPHO: A Qualitative Study and Scoping Review Using the OMERACT Process

Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0526

Comparing Immunogenicity and Safety Following Transition from Reference Rituximab to Biosimilar Rituximab (DRL_RI) in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Phase 3 Study

RA – Treatment Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].